Protein-fate regulation by YWHAZ/14-3-3ζ in cancer: phosphorylation-dependent scaffolding, competitive ubiquitin escape and therapeutic resistance

YWHAZ encodes the 14-3-3ζ isoform, which is widely implicated in cancer progression, metastasis and resistance to anticancer therapies. 14-3-3ζ is commonly described as an oncogenic scaffold or prognostic biomarker linked to PI3K/AKT, MAPK/ERK, Wnt/β-catenin, NF-κB, apoptosis, autophagy and epithelial–mesenchymal transition. Yet pathway-centered descriptions do not fully explain how a non-enzymatic phosphoprotein-binding scaffold produces diverse, context-dependent protein-fate outcomes. We develop an evidence-graded protein-fate framework in which 14-3-3ζ acts as a phosphorylation-dependent scaffold that translates phosphoprotein states into mechanistically distinct client outcomes. These include functional sequestration/accessibility control, complex/activity regulation, protein-stability regulation and, within a restricted subset of the stability/turnover spectrum, competitive ubiquitin escape. We distinguish competitive ubiquitin escape from functional sequestration and from other forms of stability regulation. Ubiquitin escape is reserved for cases in which 14-3-3ζ reduces productive access of a functionally competent E3 ubiquitin ligase to an otherwise degradation-competent substrate. β-catenin provides the clearest phosphorylation-resolved example of competitive ubiquitin escape, whereas Gli2 provides direct evidence of 14-3-3ζ-mediated beta-transducin repeat-containing protein (β-TrCP) exclusion with unresolved phosphorylation licensing. FOXO3 and BAD have ζ-demonstrated support for functional/interface sequestration, whereas BAX provides a non-ζ isoform mechanistic precedent and tuberous sclerosis complex 2 (TSC2) combines family-level mechanistic evidence with ζ-demonstrated interaction evidence. The review also addresses 14-3-3 isoform attribution and selectivity, regulation of YWHAZ expression and 14-3-3ζ abundance, autophagy and mitophagy, stress-state dependency and therapeutic resistance. Reframing 14-3-3ζ as a regulator of protein fate connects phosphorylation-dependent scaffolding to several mechanistically distinct client outcomes. Competitive ubiquitin escape is one defined subset of this biology, not a universal consequence of 14-3-3ζ binding. This evidence-graded framework may help identify context-specific dependencies on the YWHAZ/14-3-3ζ axis and guide interface-selective or degradation-restoring therapeutic strategies. Cancer cells survive and adapt to treatment partly by changing the location, activity and lifetime of proteins that control growth and cell death. YWHAZ is the gene encoding the scaffold protein 14-3-3ζ, which binds many partner proteins in a phosphorylation-dependent manner. This binding can change where a protein is located, which molecules it can interact with and, in some cases, how readily it is degraded. In this review, we propose that 14-3-3ζ is better understood as a regulator of protein fate than simply as a cancer marker or pathway-associated protein. Its binding partners are not all stabilized in the same way. For many proteins, 14-3-3ζ mainly changes localization or functional interactions; for a smaller subset with stronger mechanistic evidence, it can limit access of the protein-degradation machinery and thereby increase protein stability. We also discuss how cancer cells alter YWHAZ expression and the abundance or functional availability of 14-3-3ζ through genomic, RNA-level and protein-level mechanisms. These changes may sustain stress-adaptive signaling during therapy. Defining the specific 14-3-3ζ–client interactions required by individual tumors could enable more selective therapeutic strategies than broad inhibition of the entire 14-3-3 family.